Celltrion's (068270) autoimmune disease treatment Remsima SC has demonstrated sustained efficacy in inflammatory bowel disease (IBD) patients with a history of treatment interruption. The subcutaneous (SC) formulation showed therapeutic effects when re-administered to patients who had experienced a gap following intravenous (IV) infliximab treatment.
Celltrion announced on the 19th that it presented post-hoc analysis results from Phase 3 clinical trials of Remsima SC (infliximab) at the 2026 European Crohn's and Colitis Organisation (ECCO) Congress held in Stockholm, Sweden on the 18th (local time). ECCO is a leading global academic conference in the inflammatory bowel disease field where the latest research findings and treatment strategies are shared.
The analysis was based on Phase 3 clinical data from patients with Crohn's disease or ulcerative colitis. When infliximab SC 240mg was administered to patients who had discontinued IV infliximab treatment and received placebo for at least 16 weeks, therapeutic effects were observed in a majority of patients. Furthermore, efficacy and safety were confirmed to remain stable through the 102-week follow-up observation period.
IBD patients frequently experience temporary treatment interruptions due to various reasons including infections, side effects, and personal circumstances. This has been identified as problematic because it can lead to disease progression or increased risk of relapse.
A Celltrion official stated, "The confirmed efficacy and safety of infliximab SC in patients with treatment gaps demonstrates that the SC formulation can serve as a meaningful re-administration strategy following treatment interruption." The official added, "We will strengthen our competitiveness in autoimmune disease treatments through data-driven research and expand our position in the global market."